Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.
Mainz Biomed N.V. (NASDAQ: MYNZ) is a molecular genetics diagnostic company focused on the early detection of cancer, and its news flow reflects both scientific progress and commercial execution. Company updates frequently highlight developments around its flagship colorectal cancer screening test, ColoAlert, and its pancreatic cancer screening program, including PancAlert and related biomarker studies.
Investors and observers following MYNZ news can expect announcements on regulatory milestones, such as registrations and approvals that enable ColoAlert to be marketed in additional countries, as well as commercial partnerships with diagnostic laboratories, distributors, and digital health platforms. Examples include agreements to launch ColoAlert in Switzerland through a local laboratory partner, collaborations to introduce the test in South America, and inclusion of ColoAlert in digital preventive healthcare offerings in Germany.
News items also cover Mainz Biomed’s clinical development activities. These include updates on the eAArly DETECT and eAArly DETECT 2 studies for next generation colorectal cancer testing, presentations of clinical data on RNA‑based screening at international meetings, and feasibility and verification studies for blood‑based pancreatic cancer screening using licensed mRNA biomarkers and AI‑assisted algorithms. The company regularly announces participation in major conferences such as the American Association for Cancer Research Annual Meeting, MEDICA, and colorectal cancer screening committees organized by professional societies.
In addition, MYNZ news may include capital markets disclosures, such as securities purchase agreements, equity distribution arrangements, and summaries of financial reports filed on Form 6‑K. For readers seeking a consolidated view of these developments, this page provides a chronological feed of press releases and regulatory news that illustrate how Mainz Biomed is advancing its molecular diagnostic products, expanding market access, and managing its financing activities. Regular visits can help track scientific milestones, geographic expansion of ColoAlert, and progress in the company’s pancreatic cancer program.
Mainz Biomed (NASDAQ: MYNZ) will present initial verification results of a blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and differentiation of intraductal papillary mucinous neoplasms (IPMN) at the AACR 2026 Annual Meeting in San Diego, April 17–22, 2026.
The presentation covers a 30-subject verification study using a compact proprietary panel of blood-derived mRNA biomarkers combined with an AI-assisted modeling approach to distinguish PDAC from benign conditions including IPMN. Further details are slated for the online Proceedings of AACR.
Mainz Biomed (NASDAQ:MYNZ) reviewed 2025 highlights including clinical, regulatory, partnership, and funding progress for its cancer-detection programs.
Key items: launch of eAArly DETECT 2 (U.S. feasibility study, ~2,000 average-risk patients) to validate a next-generation CRC test; ColoAlert received MHRA and Swissmedic registrations and entered Swiss and South American distribution partnerships; pancreatic program licensed mRNA biomarkers from Liquid Biosciences with a discovery cohort (285 subjects; 35 pancreatic cancers) showing 95% sensitivity / 98% specificity, and a feasibility panel achieving 100% sensitivity / 95% specificity in a 30-subject cohort. State funding may cover up to 50% of pancreatic project costs.
Mainz Biomed (NASDAQ:MYNZ) announced that its DNA-based colorectal cancer home test ColoAlert was added to DoctorBox’s digital health portfolio on Dec 2, 2025. The move integrates Mainz Biomed’s diagnostics with DoctorBox’s platform and routes laboratory analysis to the European Oncology Lab led by Dr. Annette Buhlmann in St. Ingbert, Germany.
DoctorBox reports >1 million registered users and >10 million test results, and the partnership aims to expand at‑home access to DNA colorectal screening in Germany, where ~60,000 new colorectal cancer cases are diagnosed annually.
Mainz Biomed (NASDAQ:MYNZ) signed a Memorandum of Understanding with OncoVanguard8 to introduce ColoAlert, a DNA-based colorectal cancer screening test, to South America beginning with Peru. The MOU outlines core commercial, legal and regulatory terms and a go-to-market strategy for an initial territory, with a final distribution agreement targeted within weeks.
The companies identified Peru, Colombia and Ecuador as initial launch markets, where about 17,000 new colorectal cancer cases are diagnosed annually, highlighting demand for early-detection screening solutions that could raise participation and support public health goals.
Mainz Biomed (NASDAQ:MYNZ) will participate in MEDICA 2025 in Düsseldorf from November 17–20, 2025. MEDICA expects >5,000 exhibitors from 70 countries and about 80,000 visitors, offering a global platform for medical-technology networking, forums, and business development.
Mainz Biomed will showcase its flagship molecular stool-based colorectal cancer screening test ColoAlert and preview additional early-stage cancer diagnostic solutions. The company will be at the Rhineland-Pfalz joint booth in Hall 3, E92. Investors and attendees are directed to the company investor site for more information and social channels for updates.
Mainz Biomed (NASDAQ:MYNZ) announced it will attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) from 14–15 November 2025 in Bad Kreuznach, Germany.
The company plans to present its flagship diagnostic ColoAlert® and discuss upcoming solutions for early detection of colorectal and other cancers, engage with gastroenterology key opinion leaders, and explore clinical collaborations. Attendees are invited to visit Mainz Biomed's booth to learn about offering ColoAlert to patients.
For more information, investors and physicians are directed to the company investor site at mainzbiomed.com/investors/ and the company's social channels.
Mainz Biomed (NASDAQ:MYNZ) will attend the 2025 Maxim Growth Summit in New York City on October 22-23, 2025 at The Hard Rock Hotel NYC. The company, which focuses on molecular genetics diagnostics for early cancer detection, said it will meet one-on-one with institutional investors and senior Maxim analysts during the event.
The summit features keynote speakers and roundtable sessions across sectors including biotechnology, AI, stem cell therapy and more. For the summit agenda visit www.maximgrp.com/2025-growth-summit and for investor information visit mainzbiomed.com/investors/.
Mainz Biomed (NASDAQ:MYNZ) reported topline feasibility results for a non-invasive, blood-based pancreatic cancer screening test using 18 licensed biomarkers. In a 30-subject cohort the leading panel achieved 100% sensitivity and 95% specificity, and the algorithm also detected precancerous lesions. These results align with earlier discovery/validation datasets that showed 95% sensitivity and 98% specificity. Mainz Biomed will plan a larger confirmatory study using banked retrospective samples, then a PCR-based validation study and potential future FDA submission, pending outcomes.
Mainz Biomed (NASDAQ:MYNZ) will present groundbreaking clinical data from their eAArly DETECT study at the World Endoscopy Organization's CRC Screening Committee Meeting on October 3rd, 2025 in Berlin.
Dr. Lena Krammes will showcase the company's RNA-based diagnostic test results, which demonstrated remarkable efficacy with 97% sensitivity and specificity for colorectal cancer detection, 82% sensitivity for advanced adenomas, and 100% detection rate for advanced adenomas with high-grade dysplasia.
The presentation, titled "From Detection to Prevention," will highlight the potential of stool RNA testing in both early cancer detection and prevention through identification of high-risk lesions.
Mainz Biomed (NASDAQ:MYNZ) has announced the commercial launch of its flagship product ColoAlert® in Switzerland, marking a significant expansion of its colorectal cancer screening solution. The launch follows three key achievements: a strategic partnership with labor team w ag, one of Switzerland's leading diagnostic laboratories; regulatory approval from Swissmedic; and successful completion of technology transfer to labor team's facility in Goldach.
Additionally, the company provided an update on its eAArly DETECT 2 Study, which aims to enroll 2,000 average-risk patients. Management has decided to proceed with complete enrollment through the end of 2025 without pausing for an interim readout.
FAQ
What is the current stock price of Mainz Biomed NV (MYNZ)?
What is the market cap of Mainz Biomed NV (MYNZ)?
